On 17 April 2026, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKB BIO-B) announced the completion of its H-share full-circulation programme, converting 8.21 million Domestic and Unlisted Foreign Shares into H Shares. Trading in the converted shares will begin on the Hong Kong Stock Exchange at 9:00 a.m. on 20 April 2026.

The conversion involved three shareholders: • Wealthy Linkage Limited converted 3.63 million shares, equivalent to 1.56% of total share capital. • Future Industry Investment Fund Phase II converted 3.57 million shares, or 1.53%. • Leyue Capital Limited converted 1.01 million shares, or 0.43%.

Post-conversion, the company’s share structure is as follows: • H Shares: 170.98 million, representing 73.32% of total capital (up from 69.80%). • Domestic Shares: 62.20 million, 26.68% (down from 28.21%). • Unlisted Foreign Shares: reduced to zero from 4.64 million previously. Total share capital remains unchanged at 233.19 million shares.

The board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.